Cargando…

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer

Immune checkpoint inhibitors (ICIs) are commonly used to treat patients with advanced urothelial cancer. However, a significant number of patients do not respond to ICI, and the lack of validated predictive biomarkers impedes the success of the ICI strategy alone or in combination with chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parent, Pauline, Marcq, Gautier, Adeleke, Sola, Turpin, Anthony, Boussios, Stergios, Rassy, Elie, Penel, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486227/ https://www.ncbi.nlm.nih.gov/pubmed/37692364 http://dx.doi.org/10.1177/17588359231192402

Ejemplares similares

BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
por: Boussios, Stergios, et al.
Publicado: (2022)

Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities
por: Linares, Christian A., et al.
Publicado: (2023)

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
por: Boussios, Stergios, et al.
Publicado: (2019)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
por: Patel, Aakash, et al.
Publicado: (2021)

Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma
por: Tsai, Chung-Ying, et al.
Publicado: (2021)

Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered
por: Rassy, Elie, et al.
Publicado: (2020)

Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?
por: Moschetta, Michele, et al.
Publicado: (2020)

Unraveling the Wide Spectrum of Melanoma Biomarkers
por: Revythis, Antonios, et al.
Publicado: (2021)

The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
por: Houssiau, Hélène, et al.
Publicado: (2022)

Surgery for T4 Colorectal Cancer in Older Patients: Determinants of Outcomes
por: Osseis, Michael, et al.
Publicado: (2022)

Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
por: Revythis, Antonios, et al.
Publicado: (2022)

Applications of Proteomics in Ovarian Cancer: Dawn of a New Era
por: Ghose, Aruni, et al.
Publicado: (2022)

Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2021)

Metastatic Anorectal Melanoma Presenting as Seizures: An Infrequent Culprit
por: Galante, Joao, et al.
Publicado: (2022)

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
por: Gopalakrishnan, Dharmesh, et al.
Publicado: (2018)

Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma
por: Seront, Emmanuel, et al.
Publicado: (2018)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma—A Review
por: Walia, Arman S., et al.
Publicado: (2021)

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
por: Niegisch, Günter
Publicado: (2019)

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
por: Boll, Lilian Marie, et al.
Publicado: (2023)

An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer
por: Saxby, Helen, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing
por: Lopez-Beltran, Antonio, et al.
Publicado: (2021)

Biomarkers for predicting the efficacy of immune checkpoint inhibitors
por: Wang, Chengji, et al.
Publicado: (2022)

Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response
por: Daro-Faye, Mame, et al.
Publicado: (2020)

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
por: Boussios, Stergios, et al.
Publicado: (2020)

From Biology to Diagnosis and Treatment: The Ariadne’s Thread in Cancer of Unknown Primary
por: Mathew, Beatrice Gadiel, et al.
Publicado: (2023)

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
por: Soria, Francesco, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors
por: Lavoie, Jean-Michel, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer
por: Zhu, Alec, et al.
Publicado: (2023)

Wise Management of Ovarian Cancer: On the Cutting Edge
por: Boussios, Stergios, et al.
Publicado: (2020)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Tumor Calcification: A New Response Pattern of Myxoid Liposarcoma to Trabectedin
por: Turpin, Anthony, et al.
Publicado: (2014)

Three Prognostic Biomarkers Correlate with Immune Checkpoint Blockade Response in Bladder Urothelial Carcinoma
por: Guo, Ya, et al.
Publicado: (2022)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qgkaa4un6c8otgou8oe88d35fh